Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEBRA: Early Zoledronic Acid in Hip Fracture Patients
2023-510198-32-00Phase 4Completed
- Sponsor
- Oslo University Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hip fracture and osteoporosis comparing Zoledronic acid arm with Placebo/electrolytes arm (2 arms). Primary endpoint: Primary: Proportion with P1NP >35 µg/L at 12 months. Started Jun 2024; status: completed.
02
Drugs
zoledronic acid
03
Conditions
hip fractureosteoporosis
Beyond the preview
Go deeper on 2023-510198-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510198-32-00.